HIV-Associated Lipodystrophy Syndrome clinical trials
The registry lists 25 studies for HIV-Associated Lipodystrophy Syndrome across more than 10 countries. 0 are recruiting or about to start. 21 of them are mainly about HIV-Associated Lipodystrophy Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-05-19.
Who runs them
French National Agency for Research on AIDS and Viral Hepatitis (4) · Kirby Institute (2) · Theratechnologies (2) · Danish HIV Research Group (2) · Amsterdam UMC, location VUmc (1) · Columbia University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Weill Medical College of Cornell University (1)
What is being tested here
Drugs under test in HIV-Associated Lipodystrophy Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tesamorelin | 0 | 1 | 2 |
| Dolutegravir | 0 | 0 | 1 |
| Leptin | 0 | 0 | 1 |
| Rosiglitazone | 0 | 0 | 1 |
| Human Growth Hormone | 0 | 0 | 1 |
| Cabotegravir | 0 | 0 | 1 |
| Atazanavir | 0 | 0 | 1 |
| Pioglitazone | 0 | 1 | 1 |
Who these studies take
No HIV-Associated Lipodystrophy Syndrome study is recruiting now.
Across all 25 studies, recruiting or not: 44% stop at 75 or younger and 28% at 65; 8% take children; 0% are for women only and 16% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 25 of 25. search them.
- Body Composition and Adipose Tissue in HIVTerminatedNCT03226821Phase 41 country
- The Visceral Adiposity Measurement and Observation StudyCompletedNCT053834561 country
- Contribution of Dolutegravir to Obesity and Cardiovascular DiseaseCompletedNCT04340388Phase 41 country
- TH9507 Extension Study in Patients With HIV-Associated LipodystrophyCompletedNCT00608023Phase 36 countries
- Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTIStatus unknownNCT04887675Not applicable1 country
- Therapeutic Approaches to HAART-Induced LipodystrophyCompletedNCT00461552Phase 21 country
- Detraining in People Living With HIV/AIDSCompletedNCT03075332Not applicable1 country
- Energy Expenditure of People Living With HIV/AIDSCompletedNCT02530827
- Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin ResistanceCompletedNCT00130286Phase 1/21 country
- A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and YouthCompletedNCT000690042 countries
- An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult SubjectsCompletedNCT01848340Phase 11 country
- HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)CompletedNCT00192660Phase 41 country
- Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILECompletedNCT00383734Phase 31 country
- Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment OutcomeCompletedNCT01359917
- Study of Reyataz in HIV-infected Patients With Lipodystrophy SyndromeCompletedNCT00135356Phase 49 countries
- Polyacrylamide Hydrogel Injection in HIV-related LipoatrophyCompletedNCT01077765Phase 31 country
- Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial LipoatrophyTerminatedNCT00126308Phase 41 country
- Follow-up on the HIGH: Low Study - the Longterm Effects of Growth HormoneStatus unknownNCT006621811 country
- Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With LipodystrophyCompletedNCT00646984Phase 41 country
- MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)Status unknownNCT00122226Phase 44 countries
- Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected PatientsStatus unknownNCT00135460Phase 41 country
- Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With LipoatrophyTerminatedNCT00122655Phase 41 country
- Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive PatientsTerminatedNCT00122668Phase 41 country
- Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 PatientsTerminatedNCT00148850Phase 31 country
- Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.CompletedNCT00139178Phase 41 country